2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2 · Dec 24, 2024 · US
Antimicrobial compounds
US9108978B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9108978-B2 |
| Application number | US-201214346646-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 21, 2012 |
| Priority date | Sep 23, 2011 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A new class of biotin protein ligase (BPL) inhibitors that have antibacterial activity against multiple Staphylococcus aureus isolates, including clinically important methicillin-resistant S. aureus (MRSA) are disclosed that are non-toxic.
First claim
Opening claim text (preview).
The claims defining the invention are as follows: 1. A compound of formula (I) wherein n is an integer from 1 to 10; R 1 is selected from the group consisting of: imidazole,…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C07D495/04Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9108978B2 cover?
- A new class of biotin protein ligase (BPL) inhibitors that have antibacterial activity against multiple Staphylococcus aureus isolates, including clinically important methicillin-resistant S. aureus (MRSA) are disclosed that are non-toxic.
- Who is the assignee on this patent?
- Adelaide Res & Innovation Pty, Univ Monash
- What technology area does this patent fall under?
- Primary CPC classification C07D495/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).